After years in the making, the EU Pharma Package is closer to adoption than ever. In this week’s newsletter, we are breaking down the key consequences of its likely implementation.
Pharma Package at the Door: Healthy Regulation or the Innovation Virus?
The halls of the EU institutions are filled with chatter about one of the most important rules in the making right now. We are reaching the finish line of the legislative marathon that has been three years in the making, and many more years in the waiting. The EU Pharma Package, arguably one of the most important changes of Europe’s medicines framework in the last couple of decades, is entering its final countdown towards formal adoption. This piece of legislation represents a delicate attempt to solve the burning issue of keeping the continent an attractive hub for billion-dollar pharma R&D, while at the same time ensuring that a patient in Sofia does not have to wait months, or even years, more for a life-saving drug than a patient in Berlin.
The Ease of Access and Innovation
The crucial takeaway of this reform is the “postcode lottery”. As of right now, the availability of new medicines across the EU is relatively unequal. Innovative companies tend to launch first in wealthy markets like Germany or Denmark, while smaller Member States with lower income are left waiting, sometimes even for several years. In order to combat this, the new legislation introduces a launch mandate that has been met with anxiety within the pharmaceutical. Under the compromise reached in December last year, Member States will have the power to require marketing authorisation holders to supply their markets within three years. In the case of a company failing to comply without a duly justified reason, it will risk losing a portion of its precious regulatory protection. This is the incentive system that the Commission will try to utilise to ensure that the single market for health functions as a real single market, rather than a fragmented system.
The most interesting section of the package is perhaps the changes to Regulatory Data Protection. In the original 2023 proposal, the Commission suggested cutting the baseline protection from eight years to six, which is a move that many pharmaceutical companies saw as negative for innovation. After months of back-and-forth in the trilogues, the co-legislators landed on a more moderate, but conditional, “8+1+1+1” formula. The baseline remains at eight years of data protection, followed by one year of market protection. However, additional extensions, up to an overall cap of 11 years, are now earned and not guaranteed.
There is a bit of the leeway for additional protection, though. Companies can unlock extra protection if their product addresses an unmet medical need, if they conduct comparative clinical trials or if they secure a new therapeutic indication that offers significant clinical benefits. Strategy-wise, it is no longer enough to bring an existing drug to market – the EU is now explicitly pricing in the social value and comparative utility of innovation.
The Antimicrobial Resistance
One of the most novel additions is the transferable exclusivity voucher, designed to kickstart the development of new antibiotics. Antimicrobial resistance is often called the silent pandemic, yet the market for new antibiotics is broken, because doctors want to keep new drugs on the shelf as a last resort, meaning there is no volume-based profit for developers. The TEV allows a company that develops a priority antimicrobial to get a voucher for one additional year of data exclusivity. The transferable part is interesting, as the company can sell this voucher to another firm, which can then use it to extend the patent life of a different drug. Some have criticised this as a multi-billion-euro subsidy paid for by national budgets, the final text includes a restrictive limitation. The voucher cannot be used on any product that has seen annual sales exceeding 490 million euros. This compromise seeks to incentivise the small-cap innovators, and at the same time prevent the larger players from using the system to protect their biggest profit engines indefinitely.
The Generics and the Red Tape
The generic and biosimilar industries should pay attention to the so-called “Bolar exemption” expansion. The new rules say that generic manufacturers can start seeking regulatory approval, pricing and even participating in public tenders before the originator’s patent expires. This is intended to ensure that, as soon as the patent expires, alternatives are ready to hit the shelves, potentially saving money for some national healthcare systems. Furthermore, the European Medicines Agency will be facing some changes. Review timelines are being cut from 210 days to 180 days, and the “regulatory sandbox” concept is being codified. This should allow for the testing of frontier therapies, such as the AI-driven personalised medicine, under a more flexible oversight process.
Next Steps?
With the SANT committee vote scheduled for 18 March and a full plenary vote expected in the following months, the focus for businesses should now be adaptation. Although the new rules will not fully apply until 2028, the pipeline planning for drugs currently in Phase II or III clinical trials should begin today. The companies should assess whether the current R&D aligns with the new stricter definitions of unmet medical need and prepare for the 6-month mandatory notification period for any anticipated shortages in order to build supply chain resilience. Additionally, companies will need serious legal and logistical justifications if they choose not to launch in some Member States, or else they might risk losing their IP edge.
Through this package, Europe is offering industry a pathway to high-value innovation, but in exchange, it is demanding a level of transparency and supply security that was previously left to the market. As we move toward 2028, the regulation is expected to be tighter than before, and the companies in the sector should prepare for the new rules of the game.
